Omniome
PacBio's acquisition of Omniome, worth up to $800 million, could give it access to lucrative applications in short-read sequencing, including oncology and noninvasive prenatal testing.
Pacific Biosciences to Acquire Omniome for up to $800M, Expand Invitae Collaboration
The sequencing technology firm is also raising approximately $300 million in a PIPE financing and reported preliminary Q2 revenues of $30.5 million.
Sequencing Startup Omniome Closes $60M Series C Financing
The San Diego firm has now raised at least $145 million to drive development of its DNA sequencing platform and build manufacturing and commercial operations.